{"database": "lobbying", "table": "lobbying_activities", "rows": [[2815653, "9b7dc5f7-9a93-465c-b7ee-50175462274e", "Q2", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "GLENMARK PHARMACEUTICALS, INC., USA", 2022, "second_quarter", "PHA", "Issues related to affordability, essential medicine manufacturing and pharmaceuticals. General issues related to the generic drug industry. Issues related to H.R. 2853, the BLOCKING Act of 2021. Issues related to pharmaceutical provisions in H.R. 5376, the Build Back Better Act.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2022-07-08T12:35:09-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2815653"], "units": {}, "query_ms": 0.849609961733222, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}